iPathwayGuide's Prediction for a COVID-19 Drug Validated in Clinical Study

advaita-logo-blue-880.png New Publications: Methylprednisolone Reduces Worst COVID-19 Outcomes


Recently, Advaita announced that their advanced AI platform, iPathwayGuide, was able to predict an existing drug with clinical efficacy against COVID-19. While the manuscript undergoes peer review, a preprint describing this work is now available from Nature Research.

A second manuscript, detailing the results of an independent clinical study validating the predictions from iPathwayGuide, has been peer-reviewed and accepted for publication in Clinical Infectious Diseases. The study, undertaken at Henry Ford Health System and led by Dr. Mayur S. Ramesh, has shown in a cohort of over 200 patients that a short course of methylprednisolone was able to significantly reduce transfers to ICU, requirements for ventilation, as well as mortality.

Read more about this work and find links to both articles here

Want to find out more?

Not Getting Much from you Pathway Analysis? Use Impact Analysis Instead of Enrichment Alone

Read more here

A Comprehensive Review and Assessment of Pathway Analysis Methods

Read more here

Enquiry Form

Required fields are marked with*